Seer Inc (SEER)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.95+0.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SEER
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to grow revenue to reach $16 million to $18 million for full year 2026, representing growth over 2025.
Stated as a priority in 3 of last 3 quarters. Revenue was $2.8 million in 2026-Q1 and $3.1 million in 2026-Q2, with full year 2026 revenue guidance maintained at $16 million to $18 million, representing about 3% growth at midpoint over 2025. Management is reiterating this growth target consistently, but quarterly revenue remains below 2025 quarterly levels, indicating limited progress toward full year growth.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Seer continues to expect full year 2026 revenue to be in the range of $16 million to $18 million”
“Seer continues to expect full year 2026 revenue to be in the range of $16 million to $18 million”
“Seer expects full year 2026 revenue to be in the range of $16 million to $18 million”
Sustain gross profit margin levels despite revenue fluctuations and cost pressures.
Management stated maintaining gross profit margin as a priority in 3 of last 3 quarters. Gross profit increased from $982 thousand in 2026-Q1 to $1.5 million in 2026-Q2, with gross margin at 35% in 2026-Q1. Despite revenue declines from 2025 levels, gross margin remains stable, indicating management is maintaining margin levels but overall gross profit is lower than prior year, showing mixed delivery.
“Gross profit was $1.5 million in 2026-Q2”
“Gross profit was $982 thousand and gross margin was 35% for 2026-Q1”
“Gross profit was $2.2 million in 2025-Q4”
Continue efforts to protect and strengthen Seer's intellectual property portfolio.
Newly stated in 2026-Q1. Management reported successfully defending and reinforcing Seer's IP position through a U.S. Patent and Trademark Office Final Written Decision. No subsequent quarters restated this priority, so delivery is limited to this single event.
“Successfully defended and reinforced Seer's IP position through a U.S. Patent and Trademark Office Final Written Decision”
Drive adoption and validation of Seer's platform through collaborations and independent publications.
Newly stated in 2026-Q1. Management highlighted doubling independent publications year-over-year to 84 and securing a collaboration with Precision Health Research, Singapore. This indicates initial delivery on advancing collaborations and validation, but no further quarters restated this priority.
“Achieved a doubling of independent publications year-over-year to 84 total, accelerating third-party validation”
Over the trailing year it converted 0.63x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.